Phase 2 trial to test oral DGX-001 in patients with cognitive problems
DGX-001, an experimental oral therapy that Viage Therapeutics is developing to treat cognitive problems associated with Parkinson’s disease, appears to work as expected in people, based on data from a Phase 1 study that tested it in healthy volunteers. Results also suggested that the therapy had a positive safety…